This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified April 2005 by Hematology and Oncology Specialists.
Recruitment status was:  Recruiting
Information provided by:
Hematology and Oncology Specialists Identifier:
First received: April 11, 2005
Last updated: June 23, 2005
Last verified: April 2005
This study is designed to evaluate the efficacy and safety of single agent Doxil in the treatment of patients with refractory ITP (Idiopathic Thrombocytopenic Purpura).

Condition Intervention Phase
Autoimmune Thrombocytopenic Purpura Drug: Doxil Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

Resource links provided by NLM:

Further study details as provided by Hematology and Oncology Specialists:

Primary Outcome Measures:
  • the primary outcome would be a platelet response, with a return of platelet count to normal

Estimated Enrollment: 10
Study Start Date: September 2001
Estimated Study Completion Date: April 2005
Detailed Description:
Eligible patients will receive Doxil 20 mg/m2 IV over 1 hour every 2 weeks. Treatment will be continued for 1 course beyond return of the platelet count to normal with a maximum of 18 courses.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Thrombocytopenia with bone marrow findings showing normal or increased numbers of megakaryocytes.
  • Failure to respond to initial treatment with steroids, IV immune globulin, splenectomy and post splenectomy steroids.
  • Platelet count of 30,000 or less.
  • Performance status score of 2 or less.
  • Adequate organ function: *bilirubin< 2; *AST < 3 times normal; *creatinine < 2.
  • No prior treatment with anthracycline or chemically related drugs.

Exclusion Criteria:

  • Pregnant or lactating women.
  • Presence of a malignancy other than basal cell carcinoma of the skin.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00107913

United States, Louisiana
Hematology and Oncology Specialists Recruiting
Metairie, Louisiana, United States, 70006
Contact: Mary Ann Ostroske, RN    504-894-7115 ext 221   
Contact: Avri Haggerty, MT    504-883-2968   
Principal Investigator: Thomas M Cosgriff, MD         
Sponsors and Collaborators
Hematology and Oncology Specialists
Principal Investigator: Thomas M Cosgriff, MD Hematology and Oncology Specialists
  More Information Identifier: NCT00107913     History of Changes
Other Study ID Numbers: HOS1
Study First Received: April 11, 2005
Last Updated: June 23, 2005

Keywords provided by Hematology and Oncology Specialists:
Immune Thrombocytopenic Purpura

Additional relevant MeSH terms:
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
Blood Coagulation Disorders
Hematologic Diseases
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Blood Platelet Disorders
Immune System Diseases
Hemorrhagic Disorders
Autoimmune Diseases
Liposomal doxorubicin
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017